Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Patricia Pagnotta

Nurse Practitioner, Adult Health Maitland, FL Nurse Practitioner

NPI 1316048200 CMS profile 11060748

301 N Maitland Ave, Maitland, FL 32751

Open in the dashboard

General payments

$409,253

1,830 records reported · program years 2021–2025

Research payments

$100

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$31,250 paid to institutions, not to them · program year 2025

Through program year 2025, Patricia Pagnotta of Maitland, FL is reported in the CMS Open Payments database as having received $409,253 across 1,830 general payments and $100 in research payments paid to them. Separately, studies naming them as principal investigator received $31,250 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78,476 328
2024 General $106,115 415
2023 General $73,710 369
2022 General $83,044 387
2021 General $67,907 331
2021 Research $100 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Pagnotta
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Patricia Pagnotta were reported at $78,476. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Patricia Pagnotta Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $67,907 $138 $43–$438 $132
2022 $83,044 $165 $54–$494 $149
2023 $73,710 $178 $61–$549 $160
2024 $106,115 $186 $62–$575 $164
2025 $78,476 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. EMD Serono, Inc. $125,985 240 payments
  2. Alexion Pharmaceuticals, Inc. $63,980 148 payments
  3. E.R. Squibb & Sons, L.L.C. $44,800 71 payments
  4. Biogen, Inc. $44,774 152 payments
  5. Genzyme Corporation $38,045 84 payments
  6. TG Therapeutics, Inc. $32,131 67 payments
  7. Celgene Corporation $12,045 65 payments
  8. Janssen Pharmaceuticals, Inc $7,114 24 payments
  9. Mallinckrodt Hospital Products Inc. $6,925 31 payments
  10. Genentech USA, Inc. $6,159 89 payments
  11. Other $27,296 859 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $273,194 188 payments
  2. Travel and Lodging $50,164 158 payments
  3. Consulting Fee $46,789 40 payments
  4. Food and Beverage $36,098 1,424 payments
  5. Honoraria $2,475 1 payment
  6. Education $535 19 payments
Products named General payments · program years 2021–2025
  1. Mavenclad $101,663 92 payments
  2. ZEPOSIA $52,928 128 payments
  3. BRIUMVI $32,066 66 payments
  4. ULTOMIRIS $28,204 70 payments
  5. TYSABRI $26,333 90 payments
  6. SOLIRIS $22,641 51 payments
  7. AUBAGIO $21,406 51 payments
  8. VUMERITY $11,422 50 payments
  9. Ponvory $6,930 15 payments
  10. ACTHAR $6,925 31 payments
  11. Other $43,166 1,187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Genzyme Corporation $100 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Nurse Practitioner: 389

Drug cost

$113,563

Median for Nurse Practitioner: $21,885

Branded share of claims

100%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 11 $113,563

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 50 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Mavenclad
$37,390 — —
ZEPOSIA
$19,645 — —
ULTOMIRIS
$12,063 — —
BRIUMVI
$8,703 — —
TYSABRI
$6,162 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 50 with Patron

Records

1,831 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record